A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Pediatric Hematology & Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/08880019009033382PMID 2206854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Pilot Study of 5‐Day Continuous Infusion of High‐Dose Cisplatin and Pulsed Etoposide in Childhood Solid Tumors

  1988cited by this paper
• Ototoxicity of high-dose cis-platinum in children.

  1988cited by this paper
• High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.

  1987cited by this paper
• A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique.

  1987cited by this paper
• Carboplatin and recurrent childhood brain tumors.

  1987cited by this paper
• Phase I study of carboplatin (CBDCA) in children with cancer.

  1986cited by this paper
• Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study

  1985cited by this paper
• Results of NCI-sponsored phase I trials with carboplatin.

  1985cited by this paper
• Preclinical antitumor and toxicologic profile of carboplatin.

  1985cited by this paper
• Phase I studies with carboplatin at the Royal Marsden Hospital.

  1985cited by this paper
• Hearing loss in children receiving cisplatin chemotherapy.

  1983cited by this paper
• Cisplatin therapy in recurrent childhood brain tumors.

  1982cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.

  1981cited by this paper
• A proposed staging for children with neuroblastoma. Children's cancer study group A

  1971cited by this paper

• Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience

  2022cites this paper
• Clinical study on carboplatin for treating pediatric patients with Wilms tumors.

  2014cites this paper
• Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors

  2013cites this paper
• Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma

  2009cites this paper
• Dilemmas and pitfalls of indicating cochlear implantation in pediatric deafness caused by known and unknown inner ear lesions

  2009cites this paper
• Molecular evidence of the independent origin of multiple Wilms tumors in a case of WAGR syndrome

  2008cites this paper
• Hearing Loss in Pediatric Oncology Patients Receiving Carboplatin-containing Regimens

  2008cites this paper
• Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system

  2007cites this paper
• Risk of hearing impairment in pediatric liver transplant recipients: A single center study

  2003cites this paper
• Transient mutism following posterior fossa surgery studied by single photon emission computed tomography (SPECT)

  2002cites this paper
• Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.

  2002cites this paper
• Successful cochlear implantation in a child after recovery from a head and neck malignancy: a case report

  2002cites this paper
• TREATMENT OF ALPHA-FETOPROTEIN SECRETING HEPATOBLASTOMA BY RESPONSE OF SERUM ALPHA-FETOPROTEIN LEVELS: A New Concept

  2001cites this paper
• Dose-related nephrotoxicity of carboplatin in children

  1999cites this paper
• Controversies and new approaches to treatment of Langerhans cell histiocytosis.

  1998cites this paper
• Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

  1998cites this paper
• High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

  1997cites this paper
• A dose‐intensive, cyclophosphamide‐based regimen for the treatment of recurrent/Progressive or advanced solid tumors of childhood

  1997cites this paper
• Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.

  1996cites this paper
• Response of untreated stage IV Wilms' tumor to single dose carboplatin assessed by "up front" window therapy.

  1995cites this paper
• Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.

  1994cites this paper
• High-dose cyclophosphamide, adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor.

  1994cites this paper
• Carboplatin in pediatric malignancies.

  1994cites this paper
• Neurotoxicity secondary to antineoplastic drugs.

  1994cites this paper
• Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary?

  1993cites this paper
• Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation.

  1993cites this paper
• RESEARCH ARTICLE Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors

  year unknowncites this paper